Key result
Advanced stage light-chain cardiac amyloidosis has a median survival of approximately 6 months, highlighting the need for earlier detection and continued treatment advancements.
Highlights the poor prognosis of advanced light-chain cardiac amyloidosis and the need for early detection and continued treatment advancements.
ight chain cardiac amyloidosis (AL-CA) is a devastating disease caused by a buildup of abnormal, misfolded light chain aggregates in the myocardium. When untreated, AL-CA leads to progressive heart failure and premature death. The long-term prognosis of AL-CA is dependent on the disease stage at diagnosis and then the response to treatment. Median survival of advanced stage AL-CA at diagnosis may approximate 6 months. 1 These sobering metrics have served to motivate the detection of AL-CA in earlier stages and the continued advancements of treatment for AL-CA.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted an editorial in Light-chain cardiac amyloidosis (AL-CA). Advanced stage light-chain cardiac amyloidosis has a median survival of approximately 6 months, highlighting the need for earlier detection and continued treatment advancements.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: